1. Myeloid-derived growth factor (MYDGF) protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or a variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3, for use in treating and/or preventing cardiogenic shock.

2. The MYDGF for use according to claim 1, wherein the MYDGF comprises:

(i) SEQ ID NO: 1; or

(ii) a fragment or variant of SEQ ID NO: 1 exhibiting the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1.

3. The MYDGF for use according to claim 1, wherein the MYDGF protein consists of SEQ ID NO: 1, of SEQ ID NO: 3, or of a variant of SEQ ID NO: 3 having 99% sequence identity to SEQ ID NO: 3.

4. A nucleic acid encoding MYDGF protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or a variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3, for use in treating and/or preventing cardiogenic shock.

5. The nucleic acid for use according to claim 4, wherein the nucleic acid encodes an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1.

6. A vector comprising the nucleic acid of claim 4 or 5, for use in treating and/or preventing cardiogenic shock.

7. A host cell comprising the vector according to claim 6 and expressing the nucleic acid, for use in treating and/or preventing cardiogenic shock.

41

AMENDED SHEET (ARTICLE 19)

8. A pharmaceutical composition comprising the MYDGF protein or a fragment or a variant thereof according to any one of claims 1 to 3, the nucleic acid according to any one of claims 4 or 5, the vector according to claim 6, or the host cell according to claim 7 for use in treating and/or preventing cardiogenic shock.

9. The pharmaceutical composition for use according to claim 8, wherein said pharmaceutical composition is administered through the oral, intravenous, subcutaneous, intramucosal, intraarterial, intramuscular or intracoronary route.

10. The pharmaceutical composition for use of claim 9, wherein the administration is through one or more bolus injection(s) and/or infusion(s).

11. A method of treating and/or preventing cardiogenic shock, comprising administering to a patient in need thereof a therapeutically effective amount of MYDGF protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or fragment or variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.

12. A method of treating and/or preventing cardiogenic shock comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising myeloid-derived growth factor (MYDGF) protein comprising SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment or a variant thereof, wherein the protein or the fragment or the variant thereof exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.

13. The method according to claim 11 or 12, wherein the MYDGF comprises:

(i) SEQ ID NO: 1; or

(ii) wherein the fragment or variant is a fragment or variant of SEQ ID NO: 1 and exhibits the biological function of MYDGF, wherein the variant comprises an amino acid sequence with at least 85% amino acid sequence identity to SEQ ID NO: 1.

14. The method according to any one of claims 11 to 13, wherein the MYDGF or fragment or variant thereof is administered through one or more bolus injection(s) and/or infusion(s), preferably in a pharmaceutically accepted carrier and/or excipient.

42

AMENDED SHEET (ARTICLE 19)

15. A method for producing a non-human mammalian model of cardiogenic shock, the method comprising:

(i) transiently ligating a coronary artery of the mammal, (ii) establishing reperfusion, and

(iii) ventilating the mammal with a fraction of inhaled oxygen of about 0.18 or less.

16. The method of claim 15, wherein the non-human mammal is a rodent, preferably wherein the non-human mammal is a mouse.

17. The method of claim 15 or 16, wherein the coronary artery is ligated for about 30 minutes to about 90 minutes before reperfusion is established.

18. The method according to any one of claims 15 to 17, wherein the mammal is ventilated with a fraction of inhaled oxygen of about 0.16.

43

AMENDED SHEET (ARTICLE 19)